Market Access
Strategic Consulting
We specialize in access strategies for rare, oncology, gene and cell therapies across Europe, supporting clients navigating the transition from clinical development to commercialization.
Integrated Market Access Strategy
A successful Market Access strategy is dynamic, complex, and full of interrelated activities that work towards a successful product launch. WEP Clinical can help companies begin planning as early as phase 2 and can continue providing value at all stages leading up to accelerated launch.
MARKET RESEARCH
Is your company considering a European strategy to transition from clinical development to commercial sales?
PRICING & REIMBURSEMENT
Does your company want to understand the steps to secure premium pricing and reimbursement status across Europe?
PRODUCT COMMERCIALIZATION
Is your asset in late stage clinical development and your company wants to understand the ex-US market potential?
At WEP, our commitment to exceptional service sets us apart. We are:
Agile in our strategic thinking
Subject Matter Experts
Experienced in tactical planning
Market Research
For companies with innovative treatments moving from late-stage clinical development through to commercialization, WEP can support you to assess the global environment, analyzing true potential and create unique strategies for commercialization in Europe + UK.
Asset profiling is a deep dive approach to the evaluation of a product compromising factors such as: therapy area and unmet need; burden of disease, therapeutic positioning; clinical value.
Through our networks, we engage with Physicians & Payers to gain their insights on clinical value benefit to identify opportunities and address uncertainties.
Our team will evaluate the competitive landscape to identify relevant comparators and emerging pipelines to realize the value of your asset in the market place.
The insights gathered during the market research phase are collated to form a strategic roadmap outlining the integrated steps required to transition from clinical development through to successful commercialization in Europe and the UK.
Pricing & Reimbursement Strategy
Using our experiences in global Pharmaceutical launches, the WEP Clinical Market Access team will support your company to build an optimal pricing and reimbursement strategy to optimize premium pricing and reimbursement status across the different healthcare systems in Europe.
WEP market access team will conduct detailed pricing analysis to maximise optimal pricing potential within the EU, and identify the most appropriate comparator for your asset.
Pricing analysis informs local pricing decisions in each market and Launch sequencing for an EU+UK wide access and reimbursement strategy.
Demonstrating cost effectiveness and budget impact in the Healthcare systems will determine the strength of the reimbursement package and impact pricing strategies. The WEP team will work with you to understand your asset’s value benefit, whilst navigating the new EU HTA regulation.
Evaluation of the strength of clinical trial data, meta-analysis, Systematic Literature reviews, combined with research of both Physicians and Payers creates a deeper understanding of the clinical value within the treatment pathway and ultimately patient outcomes.
The WEP Clinical Market Access team understands the dynamics of payer-driven healthcare decisions. Our team understands all of these different variables to provide our clients with an informed, evidence-based framework for portfolio investment decisions.
Pricing & Reimbursement Strategy
Using our experiences in global Pharmaceutical launches, the WEP Clinical Market Access team will support your company to build an optimal pricing and reimbursement strategy to optimize premium pricing and reimbursement status across the different healthcare systems in Europe.
Commercialization
The WEP market access team will support your company’s asset transition from clinical development through to commercialization. We will work with your company to develop brand awareness, drive clinical experience, and build advocacy to secure access and reimbursement.
Choosing to offer pre license access to your asset via EAP/PA-NPP supports clinical experience, brand awareness, and advocacy.
WEP clinical has supported a number of clients with Early Access in France under the new legislation. Securing US equivalent pricing and collecting data to support reimbursement packages.
Commercialization in Europe starts with filing for Marketing Authorization from EMA (European Medicines Agency) and/or MHRA (Medicines Healthcare and products Regulatory Agency) which takes between 12 – 18 months to complete.
We will map the stakeholder environment to identify clinical, therapy area and patient groups across markets to enable your company to drive awareness and build networks.
The WEP market access team works closely with clients to develop launch sequencing strategies. This enables clients to accelerate access and uptake through innovative access agreements and activities, such as advanced notification programs.
SUPPORTING A MEDICINE THROUGHOUT THE DEVELOPMENT JOURNEY
Condition: Rare autoimmune disease Approved in: US and Europe